All R&D articles – Page 3
-
Business
Novartis consolidates research sites
Company will close research sites in China and Switzerland, and relocate another from Singapore to US
-
News
Half of US business R&D takes place in just five states
National Science Foundation provides state-by-state analysis of $255 billion R&D spend
-
Business
Brexit could push Japanese pharma out of the UK
Warnings that Japanese R&D investment in the UK is endangered by plans to leave the EU
-
News
Worst may still be to come for Spanish science
The effects of budget cuts from the financial crisis are still in the pipeline, scientific leaders are warning
-
Business
DuPont cuts go deep in Delaware
Following its merger with Dow, DuPont will terminate 1700 positions in Delaware, US, as part of a cost-cutting drive
-
Business
Cosmetics deals push skin 3D bioprinting
Interest for testing from L’Oréal, BASF and Procter & Gamble could be a stepping stone towards bespoke organs
-
Business
Merger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Grabbing slices of the immuno-oncology pie
Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’
-
Opinion
Be careful what you wish for
Measuring R&D productivity is a thorny issue. Dennis Lendrem urges the pharmaceutical industry to learn from its mistakes.
-
News
Spending targets for German R&D lack ambition
Expert commission says Germany can do better than goal of investing 3% of GDP on R&D by 2015
-
Business
Big pharma opens up abandoned drugs
Seven firms will make 68 stalled compounds available for academic research
-
News
China poised to become top science spender
Budgetary pressures on EU, Japan and the US have positioned China to be the highest R&D funder by around 2019, OECD says
-
News
R&D share for basic research in China dwindles
Warning that the country is too dependent on industry research that lacks novelty
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
News
Future direction of Dutch science considered
Role of private industry heads a number of issues that confront how science is put to work for society
-
News
French science needs flexibility to compete on the global stage
More money needs to be diverted to smaller research groups, while government support for industry research should be simplified
-
Business
Biotech bounced back in 2013, says report
R&D investment increasing, but industry needs to use its cash more wisely
-
Business
Pharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Megamerger brings Actavis into R&D race
$25bn Forest Labs takeover will see generics giant take on patented products